You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
You seem to be using a wider screen, would you like to enable a wider viewing experience on this page?
Meet CFO Aaron Wong who will give an update on the Q1 results and further dive into the development for NeoNavia in Europe. The event takes place Friday the 12th of May at 10.00 AM.
NeoDynamics recently released an update on deliveries of needles to hospitals in Europe. We hope to hear more about the development in Europe and who these hospitals are along with the feedback so far on the different types of needles for the NeoNavia system.
NeoDynamics AB is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of cancer. The company’s first product NeoNavia®, a new innovative pulse biopsy system for ultrasound-guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia is evaluated for breast cancer diagnosis at leading clinics in Europe and launches in the USA in 2023. NeoDynamic’s shares are listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company’s Certified Adviser is Redeye AB.
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a DigitalIR/Corporate Visibility agreement./Claus Thestrup 13:07 PM 11th of April 2023.